ClinicalTrials.gg
CompletedNCT03162783Updated Jan 16, 2025Results posted

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

A Phase 2 interventional study of ADX-102 Ophthalmic Solution (0.5%) and ADX-102 Ophthalmic Solution (0.1%) in Dry Eye Syndromes, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by Aldeyra Therapeutics, Inc. · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing reproxalap in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. reproxalap · Dry Eye Syndromes.

Enrollment
11th of 11
51 · median 158
Started
2017
the only one that year
Phase 2
5 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
11 of 11
Aldeyra Therapeutics, Inc.

Among the 11 studies testing reproxalap in Dry Eye Syndromes, this one is the 11th largest by enrollment, is the only one that started in 2017, is one of 5 in phase 2, and was the 1st registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

None of the 11 studies testing reproxalap in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →

Where they have run

About reproxalap

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing reproxalap in Dry Eye Syndromes as a file.
02

Study summary

The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.

03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

Keywords

  • Aldeyra
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 18 years of age of either gender and any race;
  • Have a reported history of dry eye for at least 6 months prior to Visit 1;
  • Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1;

Exclusion criteria

Exclusion Criteria:

  • Have any slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters;
  • Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation at Visit 1;
  • Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
  • Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
  • Have used cyclosporine 0.05% or lifitegrast 5.0% ophthalmic solution within 45 days of Visit 1;
  • Have any planned ocular and/or lid surgeries over the study period or any ocular surgery within the last 6 months;
  • Be using or anticipate using temporary punctal plugs during the study that have not been stable within 30 days of Visit 1;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    ADX-102 Ophthalmic Solution (0.5%)

    Drug: ADX-102 Ophthalmic Solution (0.5%)

  • Experimental
    ADX-102 Ophthalmic Solution (0.1%)

    Drug: ADX-102 Ophthalmic Solution (0.1%)

  • Experimental
    ADX-102 Ophthalmic Lipid Solution (0.5%)

    Drug: ADX-102 Ophthalmic Lipid Solution (0.5%)

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale.

    Change from baseline of ADX-102 on ocular discomfort in subjects with dry eye disease using the Ora Calibra® Ocular Discomfort Scale (0 = least, 4 = most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.

    Time frame: Efficacy assessment period (Day 1 through Day 29), Day 29 reported.

07

Results

Posted Jan 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneADX-102 Ophthalmic Solution (0.5%)ADX-102 Ophthalmic Solution (0.1%)ADX-102 Ophthalmic Lipid Solution (0.5%)
Started171717
Completed121611
Not completed516

Outcome measures

PrimaryEfficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale.

Change from baseline of ADX-102 on ocular discomfort in subjects with dry eye disease using the Ora Calibra® Ocular Discomfort Scale (0 = least, 4 = most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.

Time frame:
Efficacy assessment period (Day 1 through Day 29), Day 29 reported.
Reported as:
Mean · units on a scale
Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale.
units on a scaleADX-102 Ophthalmic Solution (0.1%)ADX-102 Ophthalmic Solution (0.5%)ADX-102 Ophthalmic Lipid Solution (0.5%)
Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale.-0.81 ± 0.98-0.75 ± 0.75-0.82 ± 1.33

Adverse events

Collected over The period of time over which adverse events were collected for each subject in the clinical trial was approximately four weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADX-102 Ophthalmic Solution (0.5%)0/17 (0%)0/17 (0%)17/17 (100%)
ADX-102 Ophthalmic Solution (0.1%)0/17 (0%)0/17 (0%)8/17 (47.1%)
ADX-102 Ophthalmic Lipid Solution (0.5%)0/17 (0%)0/17 (0%)17/17 (100%)
Most frequent other events
Most frequent other events
EventADX-102 Ophthalmic Solution (0.5%)ADX-102 Ophthalmic Solution (0.1%)ADX-102 Ophthalmic Lipid Solution (0.5%)
Instillation site irritationGeneral disorders17/178/1716/17
Instillation site discomfortGeneral disorders0/170/171/17
Vision blurredEye disorders1/170/171/17
Eyelid margin crustingEye disorders0/170/171/17
Ocular discomfortEye disorders0/170/171/17
DiarrheaGastrointestinal disorders1/170/170/17
EpistaxisRespiratory, thoracic and mediastinal disorders0/171/170/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ADX-102 Ophthalmic Solution (0.5%)ADX-102 Ophthalmic Solution (0.1%)ADX-102 Ophthalmic Lipid Solution (0.5%)Total
<=18 years0000
Between 18 and 65 years77418
>=65 years10101333
Sex: Female, Male
Sex: Female, Male(Participants)ADX-102 Ophthalmic Solution (0.5%)ADX-102 Ophthalmic Solution (0.1%)ADX-102 Ophthalmic Lipid Solution (0.5%)Total
Female1491134
Male38617
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ADX-102 Ophthalmic Solution (0.5%)ADX-102 Ophthalmic Solution (0.1%)ADX-102 Ophthalmic Lipid Solution (0.5%)Total
Hispanic or Latino2002
Not Hispanic or Latino15171749
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ADX-102 Ophthalmic Solution (0.5%)ADX-102 Ophthalmic Solution (0.1%)ADX-102 Ophthalmic Lipid Solution (0.5%)Total
American Indian or Alaska Native0000
Asian0202
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White16151748
More than one race0000
Unknown or Not Reported0000
Iris Color (Right Eye)
Iris Color (Right Eye)(participants)ADX-102 Ophthalmic Solution (0.5%)ADX-102 Ophthalmic Solution (0.1%)ADX-102 Ophthalmic Lipid Solution (0.5%)Total
Black0000
Blue72514
Brown613625
Hazel3148
Green1124
Gray0000
Other0000
Iris Color (Left Eye)
Iris Color (Left Eye)(participants)ADX-102 Ophthalmic Solution (0.5%)ADX-102 Ophthalmic Solution (0.1%)ADX-102 Ophthalmic Lipid Solution (0.5%)Total
Black0000
Blue72514
Brown613625
Hazel3148
Green1124
Gray0000
Other0000
08

Study locations

1 site
  • Andover Eye Associates
    Andover, Massachusetts 01810, United States
09

References and documents

Publications

  • Clark D, Sheppard J, Brady TC. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease. J Ocul Pharmacol Ther. 2021 May;37(4):193-199. doi: 10.1089/jop.2020.0087. Epub 2021 Jan 15. PubMed 33450164 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jul 2017, 1 month.

Results were first posted in Jan 2025, 7 years 6 months after primary completion. A results delay was requested in Jun 2018.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2017
First posted
May 22, 2017
StartActual
May 15, 2017
Primary completionActual
Jul 6, 2017
CompletionActual
Jul 6, 2017
Results delay requested
Jun 29, 2018
Results first posted
Jan 16, 2025
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03162783
Responsible party
Sponsor
First posted
May 22, 2017
Start date
May 15, 2017
Primary completion
Jul 6, 2017
Completion
Jul 6, 2017
Results posted
Jan 16, 2025
Last update
Jan 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Reproxalap

Start the discussion